Zura Bio reports Q2 2023 cash of $112.8M; advancing ZB-106 to Phase 2 in 2H 2024

Zura Bio Ltd

2023-Q2 EPS reported -$2.88

Cash and equivalents $112.8M at June 30, 2023, up from $1.6M at Dec 31, 2022; sufficient to fund operations through 2026.
R&D expenses $28.2M in Q2 2023 vs $0.1M in Q2 2022, driven by ZB-106 license from Eli Lilly.
G&A expenses $5.7M in Q2 2023 vs $0.8M in Q2 2022, due to higher compensation and legal/accounting costs.
Pipeline: ZB-106 Phase 2 trials for systemic sclerosis and hidradenitis suppurativa expected to start in 2H 2024; ZB-168 and ZB-880 Phase 2 trials in 2024.
Completed ~$80M private placement in June 2023; joined Russell 2000/3000 indexes.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Zura Bio Ltd reported financial results for second quarter ended June 30, 2023.

Period: second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

Zura Bio Limited (the “Company”) issued a press release announcing its second quarter 2023 results. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Zura Bio Ltd filing history →

Source: SEC EDGAR

accession 0001104659-23-091407

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.